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Tank-binding kinase I (TBK1) plays a key role in
the innate immune system by integrating signals
from pattern-recognition receptors. Here, we report
the X-ray crystal structures of inhibitor-bound
inactive and active TBK1 determined to 2.6 A˚ and
4.0 A˚ resolution, respectively. The structures reveal
a compact dimer made up of trimodular subunits
containing an N-terminal kinase domain (KD), a
ubiquitin-like domain (ULD), and an a-helical scaf-
fold dimerization domain (SDD). Activation rear-
ranges the KD into an active conformation while
maintaining the overall dimer conformation. Low-
resolution SAXS studies reveal that the missing
C-terminal domain (CTD) extends away from the
main body of the kinase dimer. Mutants that in-
terfere with TBK1 dimerization show significantly
reduced trans-autophosphorylation but retain the
ability to bind adaptor proteins through the CTD.
Our results provide detailed insights into the archi-
tecture of TBK1 and the molecular mechanism of
activation.INTRODUCTION
Inhibitor of kB kinases (IKKs) are essential regulators of the in-
flammatory, immune, and apoptotic responses. Canonical IKK
signaling is mediated by the multicomponent IKK complex,
which is composed of two kinase subunits, IKKa and IKKb,
and the regulatory scaffold subunit NEMO (nuclear factor kB
[NFkB] essential modifier; also called IKKg) (Chen et al., 1996; Di-
Donato et al., 1997; Mercurio et al., 1997; Zandi et al., 1997). The
canonical IKKs activate the transcription factor NFkB by phos-
phorylating the inhibitor of kB proteins. This phosphorylation
leads to the ubiquitination and proteasome-dependent degrada-
tion of IkB. In addition to IKKa and IKKb, the IKK kinase family
contains two noncanonical family members IKKε and TBK1
(Peters and Maniatis, 2001; Pomerantz and Baltimore, 1999;
Shimada et al., 1999). Although these two kinases have similar
biochemical properties in vitro, they have very different functions734 Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authorsin vivo (Ng et al., 2011; Tenoever et al., 2007). TBK1 is activated
by pattern-recognition receptors, such as Toll-like receptors,
and intracellular receptors, such as RIG-I, MDA5, or DAI, and
it phosphorylates IRF3 and IRF7 and other target proteins
(Cle´ment et al., 2008). TBK1 is essential for the activation of
type I interferon (IFN) in vivo, while IKKε is not. In fact, IKKε is
required for the activation of IFN-stimulated genes in vivo and
is not required for IFN expression. IKKε functions by phosphory-
lating a specific serine residue in the transcription factor STAT1,
and thereby controlling the assembly of IFN-inducible transcrip-
tion factor complexes (Ng et al., 2011; Tenoever et al., 2007). The
activation loop of TBK1 and IKKε contains only a single phos-
phoacceptor site (S172) in the T-loop but the mechanisms by
which these kinases are activated are not understood. The
canonical and noncanonical IKK kinases share 28% sequence
identity and a similar domain organization with an N-terminal
kinase domain (KD) followed by a ubiquitin-like domain (ULD),
a helical scaffold dimerization domain (SDD) and a C-terminal
domain (CTD) (Figure 1A) (Xu et al., 2011). The crystal structure
of Xenopus IKKb (xIKKb) showed that the KD and ULD associate
with the SDD indicating that the three modules operate as a
trimodular unit. The xIKKb structure also showed that dimeriza-
tion is mediated by a C-terminal region of the SDD (Xu et al.,
2011).
IKKs interact with scaffold proteins that are required for their
activation. Canonical IKKs interact with NEMO: the noncanoni-
cal TBK1 and IKKε with the adaptor proteins TANK (TRAF family
member associated NFkB activator), NAP1 (NAK-associated
protein 1), SINTBAD (similar to NAP1 TBK1 adaptor), or opti-
neurin (Fujita et al., 2003; Gatot et al., 2007; Guo and Cheng,
2007; Morton et al., 2008; Ryzhakov and Randow, 2007). These
adaptors are predicted to be structurally similar to NEMO,
which forms an elongated parallel dimeric coiled coil (Israe¨l,
2010). NEMO contains an ubiquitin-binding domain and binds
linear or K63-linked polyubiquitin chains (Baker and Ghosh,
2009). IKK activation depends on NEMO, and ubiquitination
may allow recruitment of an activating kinase such as TAK1
or may trigger IKK oligomerization, leading to trans-autophos-
phorylation in the T-loop and activation of the kinase subunits
(Baker and Ghosh, 2009). An important question is how IKK
kinases are activated and the role of ubiquitin signaling in that
process.
NFkB signaling pathways are implicated in numerous human
diseases (Karin et al., 2004). Recent findings point toward a
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Figure 1. Structure of hTBK1
(A) Cartoon showing domain boundaries for the KD, ULD, SDD, and CTD. The crystallized constructs are shown below. Inactive TBK1 was crystallized using
a construct containing a S172A mutation. Active TBK1 was crystallized using a S172-phosphorylated construct containing a D135N mutation.
(B) The KD, ULD, and SDD are shown in blue, yellow, and green, respectively. Secondary structure elements are labeled, with those in the ULD indicated with
a prime and those in the SDD by an ‘‘s’’.
(C) Structure of the hTBK1 dimer. The 2-fold symmetry axis is indicated by a dashed line.
(D) View along the 2-fold symmetry axis of TBK1.
(E and F) Structure of the xIKKb dimer for comparison.
See also Figures S1D and S1E.role of TBK1 and IKKε in oncogenic transformation. In addition
to its role in inflammatory pain and obesity, IKKε has been shown
to be upregulated in breast, ovarian and prostate cancer cell
lines and in patient-derived tumors (Adli and Baldwin, 2006;
Boehm et al., 2007; Guo et al., 2009; Mo¨ser et al., 2011; Olefsky,
2009; Pe´ant et al., 2009). TBK1 has been shown to be involved in
Ras-induced cell transformation (Barbie et al., 2009; Chien et al.,
2006; Xie et al., 2011). Recent work has identified the survival
signaling kinase AKT as a direct substrate of TBK1 (Ou et al.,
2011). As a result, TBK1 and IKKε have drawn considerable
attention and have become novel drug targets with applications
in the treatment of cancer and a variety of inflammatory diseases
including rheumatoid arthritis and obesity-related metabolicdisorders. The structures of these kinases are therefore of con-
siderable interest.
RESULTS
Crystal Structure of Inactive TBK1
We obtained crystals of a C-terminally truncated kinase frag-
ment (residues 1–657; Figure 1A) and determined the structure
in complex with specific TBK1 inhibitors (BX795 (Clark et al.,
2009, 2011), MRT67307 and MRT67215) to a resolution of
2.6 A˚ using anomalous diffraction methods with selenomethio-
nine-derivatized protein (Table S1). The construct contained
a S172A mutation that inactivates the enzyme and allowedCell Reports 3, 734–746, March 28, 2013 ª2013 The Authors 735
purification of unphosphorylated TBK1 (Figures S1A and S1B).
The entire polypeptide is well ordered, except for residues
166–174 and 187–198 of the activation loop and residues 483–
492 in the SDD, which were not modeled.
The crystals of inactive TBK1 are in space group P3221 and
contain a single copy in the asymmetric unit. Figure 1B shows
a side view of the structure with a N-terminal KD (residues
1–307), the ULD (309–384), and the all-helical SDD (408–654).
Both full-length and C-terminally truncated TBK1 are dimers in
solution (see below). A crystallographic 2-fold axis runs along
the long axis of the molecule and generates the TBK1 dimer (Fig-
ure 1C). The dimensions of the dimer are1103 1333 80 A˚ and
the overall trimodular architecture resembles that of the previ-
ously determined IKKb structure (Figure 1E; Xu et al., 2011).
However, there are major differences between the two struc-
tures. As compared to TBK1, the KD of IKKb rotates by 45,
and its center of mass translates 8 A˚ away from the dimer
axis (Figure 1E). The ULD of IKKb rotates by 30 and shifts
10 A˚ away from the dimer axis, while maintaining the attach-
ment to the SDD. As a result, the overall organization of the
kinase dimers is different: the TBK1 dimer is compact and dimer-
ization is mediated by several interfaces involving the KD, the
ULD and SDD, distributed along the entire length of themolecule
(Figure 1C). The IKKb dimer is in a more ‘‘open’’ conformation
and there are few interactions along the long axis of the mole-
cule. A small interface in the C terminus of the SDD mediates
IKKb dimerization (Figure 1E). A view along the 2-fold axis of
the dimer shows that the KDs of IKKb have rotated apart
(compare Figures 1D and 1F).
Crystal Structure of Active TBK1
The fact that the crystallized IKKb construct contains two muta-
tions (S177E/S181E) that render the kinase constitutively active
and the TBK1 construct an inactivating mutation (S172A) sug-
gested that dimer rearrangement might be part of the activation
mechanism of IKK kinases. To test this model, we determined
the 4.0 A˚ resolution crystal structure of active, S172-phosphory-
lated TBK1 containing residues 1–657 (Table S1). We obtained
these crystals from a construct containing a catalytic residue
mutation D135N (Figure 1A). This construct was monophos-
phorylated on S172 using wild-type TBK1 and crystallized in
the presence of the inhibitor BX795. The crystals of active
TBK1 are in space group P6522 and contain a single copy in
the asymmetric unit. The entire polypeptide including the activa-
tion loop is well ordered, except for residues 485– 492 in the SDD
(Figure S1D).
We find that the structure of active and inactive TBK1 superim-
pose with an rmsd of 1.5 A˚ (for 603 Ca residues) and that the
dimerization interface is maintained (Figure S1E). However, the
structures of the active and inactive KDs are significantly
different (Figure 2): the conformation of the inactive KD is similar
to that seen in the crystal structures of other inactive kinases
such as CDK2 or Src (De Bondt et al., 1993; Xu et al., 1997). Helix
aC (residues 50–62) in the catalytic domain of TBK1 is swung
outward relative to its position in the active conformation (Fig-
ure 2A). As a result of this displacement, conserved E55 is
rotated away from the active site, and the so-called ‘‘regulatory
spine,’’ assembly of which is required in active kinases, is disrup-736 Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authorsted (Kornev and Taylor, 2010). The structure of TBK1 displays
another feature characteristic of an inactive kinase conforma-
tion, which is the formation of a short 310 helix (residues 160–
164) at the beginning of the activation loop, immediately
following the conserved DFG motif (residues 157–159). This
short helix packs against the outwardly displaced helix aC and
helps to stabilize its displacement. The remainder of the activa-
tion loop, except for a stretch containing parts of helix aEF
(residues 175–186), is disordered. In contrast, in the active,
S172-phosphorylated form, the activation loop is fully ordered.
The phosphoserine makes contacts to R54 in the C helix, R134
in the catalytic loop and R162 in the activation loop (Figure 2B).
L164 shifts by 15 A˚ from its position in the inactive conformation,
resulting in remodeling of the autoinhibitory 310 helix. This allows
a 57 rotation of the C helix toward the active site. In this
conformation, E55 makes a salt bridge with K38 in b5. Reorgani-
zation of the activation loop yields a conformation that is suitable
for substrate binding. Superposition with the protein kinase A
(PKA) peptide inhibitor (PKI) complex based on alignment of
the KDs suggests that TBK1 would also favor a hydrophobic
residue at the P+1 position of the substrate (Figure S2E; Ma
et al., 2012).
Structural comparison of kinase structures shows that activa-
tion frequently requires rotation of the N-lobe relative to the
C-lobe of the KD (Lei et al., 2005; Steichen et al., 2012). Compar-
ison of the active and inactive conformations of TBK1 shows no
such structural transitions. Although activation of TBK1 does
require reorganization of the activation loop and the C helix,
this does not require repositioning of the N-lobe, and, as a result,
dimerization contacts involving N- and C-lobe of the kinase are
maintained (see below). The structure of the active KD superim-
poses with the structure of the isolated KD with an rmsd of 0.8 A˚
and is similar to that usually seen in structures of active KDs (Ma
et al., 2012).
The inhibitors bind in a similar manner to the active and inac-
tive KDs: they are positioned in the cleft between the N- and
C-lobes and occupy several subregions of the ATP binding site
to bury a surface area of 450 A˚2 (Figures 2C, 2D, and S2A–
S2D). The presence of the inhibitor stabilizes the so-called ‘‘cata-
lytic spine’’ of the kinase, which is in an assembled conformation
(Kornev and Taylor, 2010). Location of the inhibitors confirms
earlier proposals that these compounds are ATP competitive
(Clark et al., 2009). All three inhibitors share a common 2,4-bis
anilino pyrimidine core structure, which binds in a similar manner
to the hinge region of TBK1. Two hydrogen bonds are formed
between the backbone nitrogen and carbonyl group of C89 of
the kinase hinge with nitrogens in the pyrimidine and aniline
moieties (Figure 2C). The pyrimidine ring makes hydrophobic
contacts withM142 and A36, whereas the anilinemoiety is sand-
wiched between G92 and L15. The three compounds are deriv-
atized at the aniline and pyrimidine rings. In MRT67307, the
cyclopropyl group at theC5 position of the pyrimidine ringmakes
hydrophobic contacts to A36, T156, and the gatekeeper residue
M86. The cyclobutylcarboxamide moiety penetrates deepest
into the ATP binding pocket and makes hydrophobic contacts
with G18, A21, Val23 and packs against the side chain of D157
of the DFG motif. Its carbonyl group forms a hydrogen bond
with the backbone nitrogen of D157. On the other end of the
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Figure 2. Structure of Inactive and Active KD and Inhibitor Binding
(A) The inactive KD. The N-lobe is shown in light blue, the C-lobe in dark blue and structural elements of the active site in magenta. The inset displays important
components of the kinase active site: helix aC, P loop, and the catalytic residues: Asp157 (DFGmotif), Asp135 (HRDmotif), catalytic lysine Lys38, and glutamate
Glu55. The activation loop is disordered and approximate location is shown as a dotted line.
(B) The active KD. The activation loop is ordered in the pS172-phosphorylated form. The inset shows a closeup view of the activation loop with the side chains of
pS172, R54, R134, R162, and Y174 shown in stick representation. The C helix rotates by57 toward the active site allowing E55 to make a salt bridge with K38.
A network of hydrogen bonds (black dashed lines) involving the phosphate group of pS172 stabilizes the conformation of the activation loop.
(C) Fo-Fc electron density omit map for MRT67307 contoured at 2s.
(D) Interactions of MRT67307 with the KD. Generated with the program LIGPLOT.
See also Figure S2.
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(A) Interaction between KD (blue) and SDD (green).
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respectively. Carbon atoms are colored yellow
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(B) Interaction between the KD (blue) and ULD
(yellow).
(C) Interaction between the ULD (yellow) and SDD
(green).
See also Figure S3.compound, the morpholine moiety is partially buried by interact-
ing with L15, F88, and P90. MRT67307, MRT67215, and BX795
are relatively specific inhibitors of noncanonical IKK kinases but
do not inhibit IKKb or IKKa (Clark et al., 2009). We note that IKKb
and IKKa have an isoleucine instead of T156 preceding the DFG
motif, and this residue is predicted to interfere with binding of the
noncanonical IKK inhibitors, which carry a bulky substitution at
the C5 position of the pyrimidine ring. This steric interference
could explain why these compounds are specific for noncanon-
ical IKKs.
Despite low sequence identity with ubiquitin (17%), the ULD
of TBK1 adopts the compact ubiquitin-like fold that superposes
with a rmsd of 1.9 A˚ with ubiquitin (Figure S2F). The ULD is
sandwiched between the C-lobe of the KD and the SDD (Fig-
ure 1B). The hydrophobic patch of ubiquitin that is usually
responsible for binding ubiquitin effectors is conserved in the
ULD of TBK1 (Ikeda et al., 2007; Li et al., 2012). This surface
patch forms a hydrophobic interface with the SDD. The ULD
also contacts the C-lobe of the KD and is involved in dimeriza-
tion contacts. The SDD contains four long helices a1 s-a4 s that
form a left-handed, three helical antiparallel coiled coil, which
runs along the entire length of the molecule (Figure 1B). As
in IKKb, the C-lobe of the KD binds to the N-terminal end of
the SDD and the ULD binds in the middle of the SDD. The
C-terminal half of the SDD forms an extended dimerization
interface.
Interactions between the KD, ULD, and SDD
The ULD is sandwiched between the C-lobe of the KD and the
SDD and adopts a structure similar to that of the isolated domain
in solution (Ikeda et al., 2007; Li et al., 2012). A conserved patch
of the ULD forms a hydrophobic interface with helices a1 s and
a4 s of the SDD (Figure 3C). This interface is mostly hydrophobic
and buries a surface area of 1,195 A˚2 (for detailed description of738 Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authorsthe interface, see Extended Results).
The interface includes the conserved
I353. The equivalent residue of ubiquitin
(I44) is frequently involved in ubiquitin
substrate binding (Hicke et al., 2005):
burial against the SDD may explain why
no known ubiquitin-binding domain binds
the ULD (Ikeda et al., 2007). We probed
this interface by introducing a destabiliz-
ing charged residue within its hydro-phobic core (point mutant L316E) and monitored the impact
using am IFN-b-luciferase reporter assay in HEK293 cells. It
has been previously reported that TBK1 undergoes trans-auto-
phosphorylation and activation upon transfection, which we
confirmed in our assay: we observed robust induction of the
reporter with TBK1wt and phosphorylation of S172 in the activa-
tion loop, which we monitored by using a phosphospecific
antibody (Figures 4E and S4) (Fitzgerald et al., 2003). As ex-
pected, inactivating mutations K38A and S172A did not induce
reporter expression and were not phosphorylated on S172
(Figure S4). Expression of these inactivating kinase mutants
results in a dominant-negative effect by competing with and
disrupting the activity of endogenous TBK1, which is constitu-
tively expressed in this cell line (Fitzgerald et al., 2003). The
L316E mutant exhibited 6-fold lower activity than the wild-type
kinase but showed normal S172 phosphorylation (Figures 4E
and S4). Therefore, although mutagenesis of the ULD-SDD inter-
face clearly impaired IFN-b reporter induction, it did not affect
TBK1 activation.
The ULD is rigidly connected to the C-lobe of the KD by a two
residue linker between the b10 of the ULD and helix aI of the KD.
The ULD packs against a hydrophobic patch made up of aH and
aI of the C-lobe of the KD. Interaction between the two domains
buries 379 A˚2 of surface area (Figure 3B, for detailed descriptions
of the interface, see Supplemental Information). ULD residue
Y325 is buried in this hydrophobic domain interface and forms
a hydrogen bond to residue D109 of aE. Y325 is strictly con-
served in noncanonical IKKs, and mutation of this residue
to glutamate completely abolished S172 phosphorylation and
IFN-b reporter activity (Figures 4E andS4). Not surprisingly, dele-
tion of the ULD also completely abolishes kinase activity (Gon-
calves et al., 2011; Ikeda et al., 2007). Together, these data
indicate that the KD-ULD interface plays an essential role in
TBK1 kinase activation in vivo.
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(A) Interface I: interaction between the N-lobe of the KD (blue) and the SDD0 (green). Residues in the interface are shownwith carbon, nitrogen, and oxygen atoms
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(B) Interface II: interaction between the C-lobe of the KD and SDD0.
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(D) Interface IV: interaction between the two SDDs.
(E) In vivo analysis of TBK1 mutants. 293T cells were transfected with wild-type or mutants. Values represent the mean average of triplicate experiments. Error
bars indicate SEM.
(F) 293T cells were transfected with FLAG TBK1wt or mutants and HA TBK1wt. Coimmunoprecipitation (IP) experiments were performed using anti-FLAGmatrix
beads and immunoblotted (IB) for anti-HA-tagged protein. Input samples were loaded as a control.
See also Figures S3 and S4.
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TBK1 Dimerization and Implications in Kinase
Regulation
There are four dimerization interfaces that are distributed along
the entire length of the molecule: these involve the N-lobe of
the KD and the N-terminal end of the SDD (interface I), the
C-lobe of the KD and the N-terminal end of the SDD (interface
II), the ULD and the central sections of the SDD (interface III),
and the C-terminal ends of the SDD (interface IV; Figure 4). Inter-
faces I and II are small and together bury a total surface area of
345 A˚2. Interface I includes the b2-b3 loop in the N-lobe of the
KD that packs against the N-terminal end of SDD helix a4 s (Fig-
ure 4A). Interface II involves the b7-b8 loop of the C-lobe of the
kinase that packs against SDD helix a3 s (Figure 4B). Sequence
comparison shows that the KD attachment sites on the SDD are
conserved among TBK1 and IKKε orthologs and to some degree
in IKKa/b (Figure S3). Interface III, which is also conserved
among TBK1 orthologs, is mediated by mostly electrostatic
interactions involving a loop from the ULD connecting b30 and
b40 and residues from a1 s of the SDD (Figure 4C). Dimerization
buries 450 A˚2 of surface area. Interface IV is the most exten-
sive, burying620 A˚2 surface area on eachmonomer (Figure 4D).
This dimerization interface is mediated by mostly hydrophobic
interactions from helix a1 s and helix a4 s (for detailed descrip-
tion of the dimerization contacts, see Extended Results). Taken
together, the four dimerization interfaces bury a total surface
area of 1,830 A˚2 per monomer.
Onemajor difference between the TBK1 and IKKb structures is
the dimerization interface. In IKKb, the dimerization interface
is smaller (1,000 A˚2 of surface area) and is limited to the
C-terminal end of the SDD (interface IV) (Xu et al., 2011). Dimer-
ization interfaces I–III are only seen in the TBK1 structure. In
TBK1, the KD is anchored at four positions: the C-lobe of the
KD forms intramolecular contacts with the SDD and the ULD
domain (Figures 3A and 3B). In addition, the N-lobe and the
C-lobe of the KD dock against the SDD domain through dimer-
ization interfaces I and II (Figures 4A and 4B). In the IKKb struc-
ture, the KD is only anchored at one position: the C-lobe of the
KD is attached to the SDD (Figure 1E). The ULD of IKKb rotates
45 away from the C-lobe as compared to its position in TBK1.
Therefore, the KD-ULD interface as seen in TBK1 is not present
in IKKb. A view along the 2-fold axis of the dimer shows that the
KDs of IKKb have rotated apart (Figures 1C–1F). As a result, the
dimerization contacts mediated by the N- and C-lobe of the KD
and ULD (interfaces I–III) are not observed in the IKKb structure.
To investigate the role of the main dimerization interfaces
III and IV for TBK1 function, we generated mutants in each inter-
face and analyzed their impact on the biochemical properties
in vitro and functionality in vivo. Two salt bridges between
E355 and R444 as well as R357 and D452 stabilize the ULD-
SDD interface III. Double mutation of E355R and E448R, which
also packs against R357, resulted in lower activity and reduced
S172 phosphorylation (Figures 4E and S4). The SDD-SDD inter-
face IV is stabilized by a set of hydrophobic interactions between
H459E, I466E, or F470E. Mutation of these residues in com-
bination H459E/I466E/F470E lead to 2-fold decrease in ac-
tivity while maintaining autophosphorylation on S172 (Figures
4E and S4). To investigate if dimerization of mutants in vitro
correlates with dimerization in vivo, we cotransfected FLAG-740 Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authorstagged TBK1 dimerization mutants with HA-tagged TBK1wt
and performed coimmunoprecipitation experiments. Consistent
with our in vitro results, we found that all dimerization mutants
also abolished dimerization in vivo (Figure 4F).
We purified these mutants and analyzed their biochemical
properties in vitro. Full-length TBK1wt and the nonphosphory-
lated mutant TBK1S172A were dimeric in SEC-MALLS experi-
ments (Figure 5A; Table S2). The crystallization construct was
a dimer both in the nonphosphorylated (TBK1S172A_657) and
the autophosphorylated (TBK1_657) forms (Figure 5A). In IKKb,
truncation of the C terminus of the SDD leads to monomerization
but does not abolish activity (Xu et al., 2011). In TBK1, this region
of the protein is part of interface IV. To determine whether this
region is required for dimerization, we generated the truncation
1–643 (TBK1_643[S172A]), which removes the part of helix
a4 s that is important for IKKb dimerization. Remarkably, this
construct remained dimeric (Figure 5A). Further truncation
beyond residue 643 resulted in insolubility of the kinase (data
not shown). Thus, in contrast to IKKb, the C terminus of helix
a4 s is dispensable for dimerization mainly because the majority
of residues in dimerization interface IV are contributed by helix
a1 s. Indeed, mutation of helix a1 s residues H459E/I466E/
F470E (TBK1_657_HIF) resulted in monomeric TBK1, showing
that interface IV in the SDD is critical for TBK1 dimerization
(Figure 5B; Table S2). As dimerization might depend on the
phosphorylation status of TBK1, we also produced the non-
phosphorylated form TBK_657_HIF(S172A). This mutant protein
remained monomeric, showing that this interface IV mutant
disrupts dimerization independently of the phosphorylation
status (Figure 5B). Residues in interface IV are conserved only
among TBK1 orthologs, which likely explains why TBK1 does
not heterodimerize with other IKKs (Figure S3). The double
mutants E355R/E448R (TBK1_657_EE) in interface III also re-
sulted in monomeric TBK1 (Figure 5B). As expected, the
Y325E mutant in the KD-ULD interface (TBK1_657_Y) remained
dimeric.
We compared the steady-state kinetic properties of these
mutants using an in vitro kinase assay. The apparent Km value
of TBK1_657 for IRF3 was 80 mM and the apparent Vmax
55 mM, whereas the apparent Km value for ATP was 78 mM
and the apparent Vmax 50 mM (Figures 5C and 5D). The
TBK1_657_Y mutant showed 33 reduced activity (Figure 5E).
Interface III and IV mutants TBK1_657_HIF and TBK1_657_EE
had 33 and 63 reduced activity, respectively.
We verified the impact of these mutations on TBK1 activation
by monitoring S172 autophosphorylation in the kinase assay. All
mutants were already partially autophosphorylated upon over-
expression and purification from insect cells as monitored by
LC-MS and anti-pS172 immunoblotting (Figures S1A and 5F).
The degree of S172 autophosphorylation corresponded well
with that seen upon expression in HEK293 cells (Figure S4).
Whereas TBK1_657 showed a robust increase in S172 auto-
phosphorylation, the TBK1_657_Y mutant showed reduced
autophosphorylation. The dimerization mutants TBK1_657_EE
and TBK1_657_HIF also showed weak autophosphorylation.
The degree of impairment in autophosphorylation of the
mutants corresponded well to the reduced activity as seen
in the kinase assay (Figure 5E). We therefore conclude that
[ATP] μM[IRF3] μM
V 
(pm
ol/
mi
n)
V 
(pm
ol/
mi
n)
C D
E
TBK1_657
TBK1_657
Ex
ce
ss
 re
fra
ct
ive
 in
de
x 
(x1
05
)
M
ol
ec
ul
ar
 m
as
s 
(D
a)
A
TBK1S172A_643
TBK1S172A
TBK1S172A_657
TBK1_657
TBK1wt B
F
M
ol
ec
ul
ar
 m
as
s 
(D
a)
Ex
ce
ss
 re
fra
ct
ive
 in
de
x 
(x1
05
)
TBK1_657_Y
TBK1_657_HIF
TBK1_657_HIF(S172A) 
TBK1_657_EE
V
(p
m
ol
/m
in
)
0
20
40
60
80
min
TBK1Input
IB: α-TBK1
pS172 
0 0 0 015 15 15 15
Figure 5. Analysis of Dimerization Mutants
(A) Size-exclusion chromatography and multiangle laser-light-scattering profiles of purified autophosphorylated TBK1wt and mutants.
(B) Mutations in the dimerization interface result in monomeric TBK1.
(C) Kinase assay on IRF3.
(D) Measurement of apparent Km and Vmax for ATP.
(E) Kinase assay using TBK1 mutants.
(F) TBK1 activation via S172 autophosphorylation. TBK1 mutants were analyzed by anti-pS172 immunoblotting after 0 or 15 min incubation as in (E). Silver-
stained inputs are shown below.
See also Figure S1.disruption of SDD- and ULD-mediated dimerization at inter-
faces III and IV interferes with TBK1 activation by reducing
autophosphorylation.
Small Angle X-Ray-Scattering Experiments and
Interaction with the Adaptor Nap1
We next investigated the positioning of the CTD in phosphory-
lated and nonphosphorylated TBK1. We purified full-length
TBK1wt, a S172A mutant (TBK1S172A), as well as truncations
lacking the C-terminal CTD domain. Mass spectroscopy showed
that TBK1wt was phosphorylated on seven positions and thatTBK1S172A was completely devoid of phosphorylation, con-
firming that phosphorylation of the activation loop is required
for TBK1 autophosphorylation (Figures S1A and S1B). Among
the seven autophosphorylation sites, five could be identified
by phosphopeptide mapping of tryptic fragments on residues
S499, S510, S518, T542, and S632 (data not shown). We did
not observe a phosphopeptide comprising S172 in the T-loop
of the kinase. However, previous data show that overexpression
results in autophosphorylation of this residue and allows purifi-
cation of active kinase (Kishore et al., 2002; Panne et al.,
2007). Several of the phosphorylation sites observed here haveCell Reports 3, 734–746, March 28, 2013 ª2013 The Authors 741
been previously reported in TBK1 kinase isolated from cells, and
they are likely to be relevant for TBK1 regulation (Oppermann
et al., 2009). We performed three experiments to investigate
whether the TBK1 CTD folds back as originally proposed for
IKKb; however, none of the results supported the model. First,
we probed the phosphorylated and nonphosphorylated confor-
mations of TBK1 by limited proteolysis with trypsin. In non-
phosphorylated TBK1S172A, the first cleavage event occurred
C-terminal of K661, indicating that the CTD is flexibly attached
to the kinase (Figure S1C). TBK1wt yielded a similar digestion
pattern, suggesting no gross conformational changes upon au-
tophosphorylation. Second, we performed SEC-MALLS experi-
ments. Whereas major conformational rearrangements upon
autophosphorylation of the dimer would likely have yielded
altered hydrodynamic properties, the phosphorylated and non-
phosphorylated forms gave identical profiles (Figure 5A). We
used TBK1S172A truncated at K661 (TBK1S172A_661), as it
was better behaved in solution, to perform analytical ultracentri-
fugation and also confirmed that it was a dimer (Figure S5). Third,
we performed small angle X-ray scattering (SAXS) experiments
to analyze the structure of the dimer in solution and to evaluate
positioning of the CTD (Figure 6). We first measured scattering
intensity patterns from two nonphosphorylated constructs, full-
length TBK1S172A and TBK1S172A_661 (Table S2). The molec-
ular envelope calculated from the SAXS data for TBK1S172A_
661 showed excellent agreement with that calculated from the
crystal structure (c values of <3.2; Figure 6C). These envelopes
fit neatly within that calculated from the SAXS data from full-
length TBK1S172A, which contains residual volume at the
C-terminal extremity of the SDD (Figure 6C). The scattering
mass of this volume matches the expected size of the CTD, sug-
gesting that the bulk of the CTD residues are located here (Rushe
et al., 2008). These data suggest that, in inactive TBK1, the CTD
does not fold back toward the KD but is fully extended. Also,
these data show that, even in the absence of a stabilizing kinase
inhibitor, the conformation of the TBK1 dimer in solution is in
agreement with that seen in the crystal structures.
IKK kinase signaling requires interaction with scaffold pro-
teins. Whereas NEMO scaffolds assembly of IKKa and IKKb
complexes, TBK1 interacts only indirectly with NEMO through
the adaptor protein TANK (TRAF family member-associated
NFkB activator) (Pomerantz and Baltimore, 1999; Zhao et al.,
2007). In addition to TANK, three other adaptor proteins have
been shown to directly interact with TBK1: NAP1 (NFkB acti-
vating kinase associated protein 1 or 5-azacytidine-induced
protein 2 (Azi2)), SINTBAD (similar to NAP1 TBK1 adaptor) and
optineurin, all of which share a TBK1/IKKε binding domain
(TBD) predicted to form an a-helical structure (Fujita et al.,
2003; Gatot et al., 2007; Goncalves et al., 2011; Guo and Cheng,
2007; Morton et al., 2008; Ryzhakov and Randow, 2007). All four
adaptors are structurally similar to NEMO, suggesting a similar
mode of action (Chau et al., 2008). Crystallographic studies
show that NEMO forms a parallel coiled-coil homodimer and
functions as a linear platform for assembly of the IKKa/b kinases
(Israe¨l, 2010). A N-terminal IKK binding domain of NEMO associ-
ates with the C-terminal NEMO binding domain (NBD) of IKKa/b
kinase (Rushe et al., 2008). To further investigate scaffold bind-
ing and the role of TBK1 autophosphorylation in that process,742 Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authorswe expressed and purified the His-tagged TBD domain of
NAP1 (216–255) and performed pull-down assays with various
TBK1 constructs. We found that the TBD of Nap1 interacted
with full-length TBK1 irrespective of phosphorylation status (Fig-
ure 6D, lanes 5 and 7, and 9 and 11). Deletion of theC-terminal 67
residues of TBK1 abolished this interaction (Figure 6D, lanes 14
and 16), showing that NAP1 interacts in a constitutive manner
directly with the C terminus of TBK1. To investigate if disruption
of TBK1 dimerization affects adaptor binding in vivo, we cotrans-
fected TBK1 dimerization mutants and NAP1 and performed
coimmunoprecipitation experiments. We found that mutagen-
esis of dimerization interfaces did not interfere with Nap1
binding, suggesting that TBK1 dimerization is not required for
adaptor binding (Figure 6E).
DISCUSSION
The TBK1 structures presented here show that the trimodular
architecture with the KD, ULD, and SDD domains is conserved
both among canonical and noncanonical IKKs. However, the
relative domain orientations of KD, ULD, and SDD differ between
the TBK1 and IKKb kinase structures and as a result, the overall
organization of the kinase dimers is different: whereas the TBK1
dimer is compact and stabilized through extensive dimerization
interfaces, the IKKb dimer is in a more ‘‘open’’ conformation.
As IKKb was crystallized using a construct that renders the
kinase constitutively active, we considered that these structural
differences reflect different activation statuses of IKK kinases
and that reversible dimerization through interfaces I–III might
be regulatory. However, none of our results supports this model:
comparison of active and inactive TBK1 shows that activation
reorganizes the KD into an active configuration while maintaining
the compact dimer conformation. SAXS experiments also
confirm that the structure of the compact dimer is maintained
in solution even in the absence of inhibitor. We therefore rule
out the possibility that dimer opening is part of a regulatory
mechanism for TBK1.
In IKKb, dimerization is mediated by a single SDD-SDD inter-
face. The region of helix a4 s that is required for IKKb/a homo-
or heterodimerization is not essential for TBK1 dimerization.
Instead, dimerization in the C-terminal part of the SDD (dimeriza-
tion interface IV) is mediated by helix a1 s. These differences
explain why noncanonical IKKs do not heterodimerize with
canonical IKKs (Pomerantz and Baltimore, 1999). TBK1 is most
closely related in sequence to IKKε, and it has been proposed
that noncanonical IKKs also homo- and heterodimerize (Chau
et al., 2008). However, we were unable to obtain evidence for
a direct interaction between TBK1 and IKKε in immunoprecipita-
tion experiments (data not shown). Analysis of sequence conser-
vation shows that residues in the SDD dimerization interface are
conserved only among TBK1 orthologs (Figure S3). TBK1 is con-
stitutively expressed in a number of cell types, whereas IKKε
expression is inducible by various cytokines (Shimada et al.,
1999). The IFN-b gene is not activated in response to inducers
in TBK1-deficient cells, but IFN production is unaffected in
IKKε-deficient cells (Tenoever et al., 2007). Whereas TBK1-defi-
cient cells show strong defects in IFN production in response to
inducers, IFN production is induced normally in IKKε-deficient
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Figure 6. SAXS of TBK1 and Nap1 Interaction
(A) The experimental SAXS profile (log intensity [I] as a function of the momentum transfer [s]). Dots with error bars are the experimental scattering data. The
superimposition of the best-fit ab initio model generated by DAMMIN is shown as a dashed line. TBK1S172A (black), TBK1S172A_661 (red). Calculated curves
from the crystal structure as computed by CRYSOL (blue).
(B) Normalized interatomic distance distribution functions.
(C) Surface representation of the ab initio model of TBK1 kinase. The SAXS envelope of TBK1S172A is shown as a gray mesh and SAXS envelope of
TBK1S172A_661 in light blue. The middle and bottom views are rotated counter clockwise by 90 around the horizontal axis.
(D) Interaction between TBK1 and Nap1 in vitro. Pull-down of TBK1 constructs using GST-NAP1 TBK1 binding domain (TBD) showing interaction between the
NAP1 TBD and the CTD of TBK1.
(E) Interaction between TBK1mutants andNap1 in vivo. 293T cells were transfectedwith FLAGTBK1wt ormutants alone () or together withMyc-FLAGNap1 (+).
Left panel: input samples were loaded as a control. Right panel: coimmunoprecipitation (IP) experiments were performed using anti-Myc matrix beads and
immunoblotted (IB) for anti-FLAG tagged or anti-pS172 protein.
See also Figure S5.cells. However, IKKε-negative cells, unlike the TBK1 minus
cells, display a defective IFN-inducible antiviral transcriptional
response (Hemmi et al., 2004; Ng et al., 2011; Tenoever et al.,
2007). Thus, TBK1 functions primarily in the virus-inducible
expression of type I IFNs by phosphorylating IRF3 and IRF7,
while IKKε functions in the downstream IFN induction pathway
by phosphorylating STAT1 (Ng et al., 2011; Tenoever et al.,2007). It is interesting to note that both TBK1 and IKKε phos-
phorylate a specific set of serine residues in the C termini of
IRF3 and 7, while IKKε, but not TBK1, specifically phosphory-
lates serine 708 in STAT1 (Tenoever et al., 2007). We propose
that TBK1 does not heterodimerize with other IKKs, including
IKKε, consistent with the nonoverlapping functions of the two
kinases in vivo.Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authors 743
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Figure 7. Model for TBK1 Activation
Adaptor proteins such as Nap1 or optineurin bind
constitutively to the kinase CTD. Binding of K63-
linked or linear polyubiquitin chains to the UBAN
domain in the adaptor proteins triggers higher-
order oligomerization of TBK1-adaptor complexes
resulting in trans-autophosphorylation and acti-
vation of TBK1.Noncanonical IKKs contain a single phosphoacceptor site
(S172 in TBK1) in the activation loop of the KD, whereas canon-
ical IKKs contain two such sites (S177/S181 in IKKb). Whereas
phosphomimetic mutations of the phosphoacceptor sites inacti-
vate TBK1 or IKKε, such mutations in IKKa/b lead to constitutive
activation (Kishore et al., 2002). Comparison of active, pS172-
phosphorylated TBK1 with xIKKb containing phosphomimetic
residues E177 and E181 shows that these phosphoacceptor
sites play different roles in noncanonical and canonical IKKs: in
TBK1, pS172 makes several contacts with residues in the KD
resulting in stabilization of the activation segment. This coor-
dination cannot be achieved by phosphomimetic residues. In
contrast, in the ordered activation segment of IKKb, the E177
and E181 residues are mostly solvent exposed indicating the
different roles of the phosphoacceptor sites in regulating nonca-
nonical and canonical IKKs.
The geometry of TBK1, with the two KDs positioned on oppo-
site faces of the dimer, precludes autophosphorylation and
activation in cis. It is likely that activation requires trans-auto-744 Cell Reports 3, 734–746, March 28, 2013 ª2013 The Authorsphosphorylation through higher-order
oligomerization of TBK1dimers (Figure 7).
In agreement with this model, mutants
that interfere with TBK1 dimerization
show significantly reduced trans-
autophosphorylation. One possibility is
that trans-autophosphorylation occurs
through an activation loop swapped
intermediate in which the S172 from one
protomer is located in close proximity to
the active site of a neighboring protomer
(Ma et al., 2012). Once activated, mono-
meric KD or full-length TBK1 displays
comparable kinase activities showing
that higher-order oligomerization is not
essential to maintain kinase activity after
activation (Ma et al., 2012). Similarly,
IKKb dimerization is required for activa-
tion, but dimerization is not required for
activity once the activation loop is phos-
phorylated (Xu et al., 2011). We therefore
conclude that dimerization is required for
TBK1 kinase activation but not for activity
once the kinase is activated.
Adaptor proteins such as NEMO for
IKKa/b and TANK, NAP1, SINTBAD, and
optineurin for TBK1/IKKε form parallel
coiled-coil homodimers that constitu-
tively bind to the kinase CTD in a mutuallyexclusive manner (Figure 6C) (Goncalves et al., 2011). Disruption
of TBK1 dimerization does not abolish interaction with Nap1
showing that kinase dimerization is not a prerequisite for adaptor
binding. This is in agreement with the structure of the NEMO/IKK
kinase associating domain in complex with segments of the
IKKa/b, which shows that the NEMO dimer binds two IKK frag-
ments independently (Rushe et al., 2008). However it is likely
that adaptor binding stabilizes the C terminus of the kinase dimer
and is important for TBK1 activation under physiological cir-
cumstances (Goncalves et al., 2011). Several adaptor proteins
contain ubiquitin-binding domains that bind K63-linked or linear
polyubiquitin chains, and ubiquitin binding appears to contribute
to TBK1 activation (Gleason et al., 2011; Liu and Chen, 2011).
One possibility is that binding of polyubiquitin chains triggers
higher-order oligomerization of TBK1-adaptor complexes, re-
sulting in trans-autophosphorylation and activation of the kinase
(Figure 7). A similar mode of activation has been proposed for
the TAK1 kinase complex (Xia et al., 2009). In addition, recent
studies have shown that TBK1 is polyubiquitinated on the KD
by K63-linked chains, which allows recruitment of NEMO (Fried-
man et al., 2008; Wang et al., 2012). An important question is if
and how direct ubiquitination or ubiquitin binding to the adaptor
proteins triggers kinase oligomerization and activation.
EXPERIMENTAL PROCEDURES
Structure Determination, Refinement, and Analysis
The structure of inactive TBK1 was determined by single-wavelength anoma-
lous dispersion (SAD) in space group P3221 at 3.2 A˚ resolution, from a seleno-
methione-labeled crystal of TBK1. Heavy atom parameter refinement and SAD
phase calculations were performed with SHARP using anomalous signal from
14 selenomethionine sites. The electron density map was improved with
solvent flattening using SOLOMON. SAD phasing statistics from 32 to 4.0 A˚
resolution included a phasing power (anomalous) of 2.35 an Rcullis (anomalous)
of 0.50 and a mean figure of merit of 0.449. A final model for TBK1 was
produced by iterative rounds of manual model building in Coot and refinement
using PHENIX. The Dundee PRODRG2 Server was used to generate topology
and restraint files of the inhibitor compounds for refinement. The final model
contains residues 1–657 and was refined to a 2.6 A˚ resolution with an Rwork
and an Rfree of 24% and 27%, respectively. No electron density was observed
for residues 166–174 and 187–198 in the activation loop and residues 483–
491 in the SDD. The register of helix a2 s of the SDD was verified by an anom-
alous difference map obtained from a selenomethione-labeled L508Mmutant.
Refinement was carried out by applying secondary structure restraints in the
initial rounds of refinement. Analysis of the refined structure by MolProbity
showed that there are no residues in disallowed regions of the Ramachandran
plot and no residues in disallowed regions. TheMolProbity all atom clash score
was 11.0, placing the structure in the 93rd percentile (with 100th best) of struc-
tures refined at 2.6 A˚ or lower resolution. The structure of active TBK1 was
determinedbymolecular replacement in spacegroupP6522 at 4.0 A˚ resolution,
using aKD-ULD fragment as the searchmodel. After positioning of theKD-ULD
fragment, additional density for the SDDwas apparent in a 2F0-Fcmap. The full
KD-ULD-SDD chain was obtained by superposition of the full TBK1 chain onto
the partial KD-ULDmodel. Amodel of the KD in the active conformation (4EUU)
was used to build the activation loop (Ma et al., 2012). A final model for active
TBK1 was produced by manual model building in Coot and refinement using
PHENIX. For further details, please refer toExtendedExperimentalProcedures.
ACCESSION NUMBERS
The atomic coordinates have been deposited in the Protein Data Bank under
ID codes 4IW0 (TBK1 active, ligand BX795), 4IWO (TBK1 inactive, ligand
MRT67215), 4IWP (TBK1 inactive, ligand BX795), and 4IWQ (TBK1 inactive,
ligand MRT67307).
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